A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics

Mary B. Wilwerding, Charles Lawrence Loprinzi, James A. Mailliard, Judith R. O'Fallon, Angela W. Miser, Carol van Haelst, Debra L. Barton, John F. Foley, Laurie M. Athmann

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Sedation may be a doselimiting side-effect of opioid therapy in some cancer patients. This study was designed to evaluate further the use of the psychostimulant, methylphenidate, an agent that has been reported to counteract opioid-induced sedation, in patients with cancer-related pain. Patients receiving a stable dose of an opioid for cancer-related pain were recruited for this randomized, double-blind, crossover clinical trial. In addition to their regular dose of narcotics, they received 5 days of methylphenidate followed by 5 days of placebo, or vice versa. Our data did not definitively demonstrate any statistically significant benefit for methylphenidate, but did suggest that this drug could mildly decrease narcotic-induced drowsiness and could increase night-time sleep. These data, in conjunction with other published data, suggest that methylphenidate can counteract narcotic-induced daytime sedation to a limited degree.

Original languageEnglish (US)
Pages (from-to)135-138
Number of pages4
JournalSupportive Care in Cancer
Volume3
Issue number2
DOIs
StatePublished - Mar 1995

Fingerprint

Methylphenidate
Narcotics
Opioid Analgesics
Neoplasms
Sleep Stages
Cross-Over Studies
Sleep
Placebos
Clinical Trials
Pharmaceutical Preparations
Cancer Pain
Therapeutics

Keywords

  • Methylphenidate
  • Narcotic-induced sedation
  • Psychostimulants

ASJC Scopus subject areas

  • Nursing(all)
  • Oncology

Cite this

Wilwerding, M. B., Loprinzi, C. L., Mailliard, J. A., O'Fallon, J. R., Miser, A. W., van Haelst, C., ... Athmann, L. M. (1995). A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. Supportive Care in Cancer, 3(2), 135-138. https://doi.org/10.1007/BF00365854

A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. / Wilwerding, Mary B.; Loprinzi, Charles Lawrence; Mailliard, James A.; O'Fallon, Judith R.; Miser, Angela W.; van Haelst, Carol; Barton, Debra L.; Foley, John F.; Athmann, Laurie M.

In: Supportive Care in Cancer, Vol. 3, No. 2, 03.1995, p. 135-138.

Research output: Contribution to journalArticle

Wilwerding, MB, Loprinzi, CL, Mailliard, JA, O'Fallon, JR, Miser, AW, van Haelst, C, Barton, DL, Foley, JF & Athmann, LM 1995, 'A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics', Supportive Care in Cancer, vol. 3, no. 2, pp. 135-138. https://doi.org/10.1007/BF00365854
Wilwerding, Mary B. ; Loprinzi, Charles Lawrence ; Mailliard, James A. ; O'Fallon, Judith R. ; Miser, Angela W. ; van Haelst, Carol ; Barton, Debra L. ; Foley, John F. ; Athmann, Laurie M. / A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. In: Supportive Care in Cancer. 1995 ; Vol. 3, No. 2. pp. 135-138.
@article{4f73ff71ad054740a7bfc49ea2245827,
title = "A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics",
abstract = "Sedation may be a doselimiting side-effect of opioid therapy in some cancer patients. This study was designed to evaluate further the use of the psychostimulant, methylphenidate, an agent that has been reported to counteract opioid-induced sedation, in patients with cancer-related pain. Patients receiving a stable dose of an opioid for cancer-related pain were recruited for this randomized, double-blind, crossover clinical trial. In addition to their regular dose of narcotics, they received 5 days of methylphenidate followed by 5 days of placebo, or vice versa. Our data did not definitively demonstrate any statistically significant benefit for methylphenidate, but did suggest that this drug could mildly decrease narcotic-induced drowsiness and could increase night-time sleep. These data, in conjunction with other published data, suggest that methylphenidate can counteract narcotic-induced daytime sedation to a limited degree.",
keywords = "Methylphenidate, Narcotic-induced sedation, Psychostimulants",
author = "Wilwerding, {Mary B.} and Loprinzi, {Charles Lawrence} and Mailliard, {James A.} and O'Fallon, {Judith R.} and Miser, {Angela W.} and {van Haelst}, Carol and Barton, {Debra L.} and Foley, {John F.} and Athmann, {Laurie M.}",
year = "1995",
month = "3",
doi = "10.1007/BF00365854",
language = "English (US)",
volume = "3",
pages = "135--138",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics

AU - Wilwerding, Mary B.

AU - Loprinzi, Charles Lawrence

AU - Mailliard, James A.

AU - O'Fallon, Judith R.

AU - Miser, Angela W.

AU - van Haelst, Carol

AU - Barton, Debra L.

AU - Foley, John F.

AU - Athmann, Laurie M.

PY - 1995/3

Y1 - 1995/3

N2 - Sedation may be a doselimiting side-effect of opioid therapy in some cancer patients. This study was designed to evaluate further the use of the psychostimulant, methylphenidate, an agent that has been reported to counteract opioid-induced sedation, in patients with cancer-related pain. Patients receiving a stable dose of an opioid for cancer-related pain were recruited for this randomized, double-blind, crossover clinical trial. In addition to their regular dose of narcotics, they received 5 days of methylphenidate followed by 5 days of placebo, or vice versa. Our data did not definitively demonstrate any statistically significant benefit for methylphenidate, but did suggest that this drug could mildly decrease narcotic-induced drowsiness and could increase night-time sleep. These data, in conjunction with other published data, suggest that methylphenidate can counteract narcotic-induced daytime sedation to a limited degree.

AB - Sedation may be a doselimiting side-effect of opioid therapy in some cancer patients. This study was designed to evaluate further the use of the psychostimulant, methylphenidate, an agent that has been reported to counteract opioid-induced sedation, in patients with cancer-related pain. Patients receiving a stable dose of an opioid for cancer-related pain were recruited for this randomized, double-blind, crossover clinical trial. In addition to their regular dose of narcotics, they received 5 days of methylphenidate followed by 5 days of placebo, or vice versa. Our data did not definitively demonstrate any statistically significant benefit for methylphenidate, but did suggest that this drug could mildly decrease narcotic-induced drowsiness and could increase night-time sleep. These data, in conjunction with other published data, suggest that methylphenidate can counteract narcotic-induced daytime sedation to a limited degree.

KW - Methylphenidate

KW - Narcotic-induced sedation

KW - Psychostimulants

UR - http://www.scopus.com/inward/record.url?scp=0029263950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029263950&partnerID=8YFLogxK

U2 - 10.1007/BF00365854

DO - 10.1007/BF00365854

M3 - Article

C2 - 7539701

AN - SCOPUS:0029263950

VL - 3

SP - 135

EP - 138

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 2

ER -